Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA treat-to-target trial in early rheumatoid arthritis
NL-OMON44989Not yet recruiting
- Sponsor
- VU University Medical Center
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methotrexate, prednisolone, prednisone, 5-aminosalicylic acid + sulphasalazine and hydroxychloroquine in rheumatoid arthritis (RA) (6 arms), sponsored by VU University Medical Center. Primary endpoint: EULAR good response at 26 weeks. Planned start May 2014; status: not yet recruiting.
02
Drugs
methotrexateprednisoloneprednisone5-aminosalicylic acid + sulphasalazinehydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON44989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44989.